Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 185 publications
Project 5 in 5: Paving the Way for Increasing Pragmatism in Clinical Oncology Trials.
Journal: JCO oncology practice
Published: January 09, 2026
US Food and Drug Administration Approval Summary: Inavolisib With Palbociclib and Fulvestrant for Endocrine-Resistant, PIK3CA-Mutated, Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative, Locally Advanced or Metastatic Breast Cancer.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: August 22, 2025
US Food and Drug Administration Approval Summary: Ribociclib With an Aromatase Inhibitor in the Adjuvant Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Stage II and III High-Risk Early Breast Cancer Treatment Setting.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: August 11, 2025
Modernizing Research and Evidence Consensus Definitions: A Food and Drug Administration-National Institutes of Health Collaboration.
Journal: JAMA network open
Published: June 17, 2025
Overall Survival and the Evolving Benefit-Risk Assessment for Poly (ADP-ribose) Polymerase Inhibitors in Advanced Ovarian Cancer.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: May 19, 2025
The Food and Drug Administration pooled analysis of overall survival according to depth of response in frontline advanced immune-oncology renal cell carcinoma trials.
Journal: JNCI cancer spectrum
Published: April 21, 2025
Challenges in Automating Extraction of Real-World Radiographic Images and Adverse Events: Lessons From the ICAREdata Initiative.
Journal: JCO clinical cancer informatics
Published: April 18, 2025
FDA Approval Summary: Datopotamab Deruxtecan-dlnk for Treatment of Patients with Unresectable or Metastatic, HR-Positive, HER2-Negative Breast Cancer.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: April 16, 2025
FDA approvals in 2024: new options for patients across cancer types and therapeutic classes.
Journal: Nature reviews. Clinical oncology
Published: April 11, 2025
FDA Approval Summary: Vorasidenib for IDH-Mutant Grade 2 Astrocytoma or Oligodendroglioma Following Surgery.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: April 11, 2025
FDA Approval Summary: Nogapendekin Alfa Inbakicept-pmln with BCG for BCG-Unresponsive Carcinoma In Situ.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: April 08, 2025
Last Updated: 09/26/2026